Latest Articles
Biomarkers and Immunotherapy in Endometrial Cancer: Mechanisms and Clinical Applications - Frontiers
Biomarkers and Immunotherapy in Endometrial Cancer: Mechanisms and Clinical Applications Frontiers
Published: Oct. 6, 2025, 5:06 p.m.
Early-onset uterine cancer research seeks new therapy development for younger patients - Today@Wayne
Early-onset uterine cancer research seeks new therapy development for younger patients Today@Wayne
Published: Oct. 6, 2025, 4:10 p.m.
Woman’s stage 4 endometrial cancer treated successfully with combination therapy - MultiCare
Woman’s stage 4 endometrial cancer treated successfully with combination therapy MultiCare
Published: Sept. 26, 2025, 9:56 a.m.
Menstrual pain management and the lack of targeted therapy in Bangladesh - The Daily Star
Menstrual pain management and the lack of targeted therapy in Bangladesh The Daily Star
Published: Sept. 23, 2025, 10:50 a.m.
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer - The ASCO Post
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer The ASCO Post
Published: Sept. 19, 2025, 2:31 p.m.
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes - The ASCO Post
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes The ASCO Post
Published: Sept. 19, 2025, 2:23 p.m.
Cartherics awarded at 2025 Asia Pacific Cell & Gene Therapy Excellence Awards - BioMelbourne Network
Cartherics awarded at 2025 Asia Pacific Cell & Gene Therapy Excellence Awards BioMelbourne Network
Published: Sept. 15, 2025, 5:03 a.m.
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards - BioInformant
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards BioInformant
Published: Sept. 13, 2025, 9:33 a.m.
FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation - Nature
FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation Nature
Published: Sept. 13, 2025, 5:58 a.m.
Specialty Influences Postcancer Hormone Therapy Prescribing - Medscape
Specialty Influences Postcancer Hormone Therapy Prescribing Medscape
Published: Sept. 11, 2025, 1:07 p.m.
Link copied to clipboard!